AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Gamma-aminobutyric acid receptor subunit gamma-2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P18507

UPID:

GBRG2_HUMAN

Alternative names:

GABA(A) receptor subunit gamma-2

Alternative UPACC:

P18507; F5HB82; Q6GRL6; Q6PCC3; Q9UDB3; Q9UN15

Background:

Gamma-aminobutyric acid receptor subunit gamma-2, also known as GABA(A) receptor subunit gamma-2, plays a pivotal role in the brain's inhibitory signaling by forming ligand-gated chloride channels. This protein is essential for the development of functional inhibitory GABAergic synapses, contributing to synaptic inhibition as a GABA-gated ion channel. Its interaction with different alpha and beta subunits influences the formation of synaptic contacts, highlighting its significance in neurodevelopment.

Therapeutic significance:

The protein's involvement in various epileptic conditions, including Developmental and epileptic encephalopathy 74, Epilepsy, childhood absence 2, Febrile seizures, familial, 8, and Generalized epilepsy with febrile seizures plus 3, underscores its therapeutic significance. Understanding the role of Gamma-aminobutyric acid receptor subunit gamma-2 could open doors to potential therapeutic strategies for these debilitating neurological disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.